Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of entinostat added to continued aromatase inhibitor therapy in progressing ER-positive metastatic breast cancer
2007-006415-23Phase 2Completed
- Sponsor
- Syndax Pharmaceuticals
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of entinostat in breast cancer, sponsored by Syndax Pharmaceuticals. Primary endpoint: Clinical benefit rate during first 6 cycles. Started Feb 2008; status: completed.
02
Drugs
entinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-006415-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006415-23.